 Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks. Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder cPTSD as measured by the Clinician Administered PTSD Scale CAPS-5, compared with the response to placebo. 